Evidence map›Paper›PMID 39887618›Full record

ArticleAdvanced healthcare materials2025

Bioprinted Micro-Clots for Kinetic Analysis of Endothelial Cell-Mediated Fibrinolysis.

Jonathan J Chang, Kelsey Brew, Jamie A G Hamilton, Varun Kumar, José A Diaz, Shuichi Takayama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jonathan J ChangWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA.ORCID 0000-0003-2956-622X
Kelsey BrewWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA.
Jamie A G HamiltonWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA.ORCID 0000-0003-3071-6029
Varun KumarWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA.
José A DiazDivision of Surgical Research, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Shuichi TakayamaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA.ORCID 0000-0002-4385-9080

Funding

Atlanta Network for Training In KUH Scientific Research (ATLANTIS)TL1DK136047 · NIDDK · EMORY UNIVERSITY · PI Vivien Andrea Sheehan · 2022 to 2026
$3.0M
Atlanta Network for Training In KUH Scientific Research (ATLANTIS)U2CDK129501 · NIDDK · EMORY UNIVERSITY · PI Stacy Stephans Heilman · 2022 to 2026
$2.9M
Engineered Heterochronic Parabiosis on 3D Microphysiological SystemsR01AG072309 · NIA · GEORGIA INSTITUTE OF TECHNOLOGY · PI JANG, YOUNG CHARLES · 2021 to 2025
$1.9M
3D High Throughput Model to Predict Drug Efficacy in Fibrosis Progression vs ReversalR21AG061687 · NIA · GEORGIA INSTITUTE OF TECHNOLOGY · PI HECKER, LOUISE, TAKAYAMA, SHUICHI · 2019 to 2020
$445k
Atlanta Network for Training In KUH Scientific ResearchNational Science Foundation EF2319391National Science Foundation EF2319430National Science Foundation Graduate Research Fellowship Program DGE-2039655NIA NIH HHS R01 AG072309NIA NIH HHS R21 AG061687NIDDK NIH HHS TL1 DK136047NIDDK NIH HHS TL1DK136047NIDDK NIH HHS U2C DK129501NIDDK NIH HHS U2CDK129501NIH HHS R01 AG072309
6 · The paper itself

Abstract

Vascular hypo-fibrinolysis is a historically underappreciated and understudied aspect of venous thromboembolism (VTE). This paper describes the development of a micro-clot dissolution assay for quantifying the fibrinolytic capacity of endothelial cells - a key driver of VTE development. This assay is enabled using aqueous two-phase systems (ATPS) to bioprint microscale fibrin clots over human umbilical vein endothelial cells (HUVECs). Importantly, these micro-clots are orders of magnitude smaller than conventional fibrin constructs and allow HUVEC-produced plasminogen activators to mediate visually quantifiable fibrinolysis. Using live-cell time-lapse imaging, micro-clot dissolution by HUVECs is tracked, and fibrinolysis kinetics are quantified. The sensitivity of cell-driven fibrinolysis to various stimuli is rapidly tested. The physiological relevance of this convenient high-throughput assay is illustrated through treatments with lipopolysaccharide (LPS) and rosuvastatin that elicit anti- and pro-fibrinolytic responses, respectively. Furthermore, treatment with baricitinib, an anti-inflammatory therapeutic found to increase cardiovascular risks after market approval, provokes an anti-fibrinolytic response - which highlights the potential role of endothelial cells in increasing VTE risk for patients receiving this drug. This endothelial cell fibrinolysis assay provides a high-throughput and versatile drug testing platform - potentially allowing for early preclinical identification of therapeutics that may beneficially enhance or adversely impair endothelial fibrinolysis.

Indexed as

FibrinolysisHuman Umbilical Vein Endothelial CellsThrombosisFibrinHumansKineticsVenous ThromboembolismFibrinendothelial cellsfibrinolysismicro‐physiological systemsthrombosis

Identifiers

PMID39887618
PMCPMC11912099

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.